Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents.
暂无分享,去创建一个
A. Stamatoullas | K. Götze | D. Steensma | P. Fenaux | S. Thépot | M. Sekeres | U. Germing | I. Kotsianidis | J. Hamel | Sophie Park | V. Santini | G. Sanz | R. Komrokji | C. Kelaidi | E. Balleari | A. Toma | M. D. Campelo | Agnes Guerci Bresler | M. Campelo
[1] M. Cazzola,et al. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. , 2020, The New England journal of medicine.
[2] G. Garcia-Manero,et al. Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. , 2019, Blood.
[3] M. Delforge,et al. A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes , 2017, Leukemia.
[4] A. Stamatoullas,et al. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] K. Götze,et al. Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study , 2016 .
[6] A. Stamatoullas,et al. A randomized phase II trial of azacitidine +/− epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents , 2016, Haematologica.
[7] A. Stamatoullas,et al. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion , 2016, Leukemia.
[8] P. Campbell,et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. , 2015, Blood.
[9] P. Fenaux,et al. A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q) , 2013, Leukemia.
[10] M. Cazzola,et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] H. Dombret,et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. , 2008, Blood.
[12] E. Hellström-Lindberg,et al. Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes. , 2008, Seminars in hematology.
[13] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.